Before considering commencing a child or adult on an immuno-suppressive drug, it is 83 important to identify potential triggers, such as irritants, and exacerbating factors (such 84 as immediate and delayed hypersensitivity) through allergy testing (skin prick testing, specific IgE as well as patch testing). 3 In addition, reasons why topical treatments have 86 failed need to be taken into account. Applying creams and ointments is labour intensive 87 and time consuming. Patient education on their use has a proven additional benefit with 88 regard to both disease severity and quality of life. 4 Sometimes, admitting a patient for a 89 few days for education and intensive topical therapy can be helpful, and also can as a prophylactic measure reduces the risk of disease flares. 5 In young children, 97 occlusive garments (wet wraps) are commonly used as a short-term therapy to reduce 98 more generalised eczematous inflammation and some centres also use them for long-99 term treatment of severe cases. However, there is limited RCT evidence, long-term 100 studies that evaluate systemic absorption and skin atrophy are lacking and their use is 101 rather impracticable in adults. 6 
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With regard to immuno-suppressive treatments, there is a paucity of published 104 evidence to guide clinical practice, especially in children, and prescribing therefore has to be guided by experience in adults and the use of these drugs in other severe 106 childhood inflammatory disorders, such as rheumatoid arthritis or inflammatory bowel 6 disease. 7 about the potential long-term risk of lymphoma based on observations in inflammatory 147 bowel disease, but the risk increase seen may be related to inflammatory bowel disease 148 itself rather than be drug-related. 12 More recently the emergence of progressive 
Methotrexate

164
As with azathioprine, the mechanism of action of methotrexate in AD is not fully 165 understood, but it is known to have anti-inflammatory properties and to also reduce 
Azathioprine
Dose: initially 1mg/kg/day, increase to max 3mg/kg/day, taking account of TPMT result TPMT <3nmol/h/mL -contraindicated, TPMT 3-8 nmol/h/mL -low dose 0.5-1mg/kg/day, TPMT 8-14.5 nmol/h/mL 1-3mg/kg/day, TPMT >14.5 nmol/h/mL consider >3mg/kg/day if no response Drug monitoring: FBC, renal, liver profile and TPMT levels at baseline, then weekly for first month, then once every three months. Increases in dose should be accompanied by weekly blood tests.
Repeat blood count if severe throat infection of other signs of potential marrow suppression.
Methotrexate
Dose: initially 200micrograms/kg once weekly increased to max 400 micrograms/kg once weekly, depending on response, test dose is usually given at start of therapy, followed by bloods a week later; subcutaneous route can be used if oral route is ineffective or nausea is severe; folic acid is given at least once weekly in conjunction with methotrexate (5mg weekly, on different day).
However, folic acid regimens vary and evidence is not conclusive as to which is most efficacious. 
